Csanády, L. (2000). Rapid kinetic analysis of multichannel records by a simultaneous fit to
all dwell-time histograms. Biophys. J. 78: 785–799.
Dalemans, W., Barbry, P., Champigny, G., Jallat, S., Dott, K., Dreyer, D., et al. (1991).
Altered chloride ion channel kinetics associated with the deltaF508 cystic fibrosis mutation.
Nature 354: 526–528.
Davies, J.C., Wainwright, C.E., Canny, G.J., Chilvers, M.A., Howenstine, M.S., Munck, A.,
et al. (2013). Efficacy and safety of Ivacaftor in patients aged 6 to 11 years with cystic
fibrosis with a G155D mutation. Am. J. Respir. Crit. Care Med. 187: 1219–1225.
Denning, G.M., Anderson, M.P., Amara, J.F., Marshall, J., Smith, A.E., and Welsh, M.J.
(1992). Processing of mutant cystic fibrosis transmembrane conductance regulator is
temperature-sensitive. Nature 358: 761–764.
Farinha, C.M., King-Underwood, J., Sousa, M., Correia, A.R., Henriques, B.J., Roxo-Rosa,
M., et al. (2013). Revertants, Low Temperature, and Correctors Reveal the Mechanism of
F508del-CFTR Rescue by VX-809 and Suggest Multiple Agents for Full Correction. Chem.
Biol. 20: 943–955.
Farinha, C.M., Sousa, M., Canato, S., Schmidt, A., Uliyakina, I., and Amaral, M.D. (2015).
Increased efficacy of VX-809 in different cellular systems results from an early stabilization
effect of F508del-CFTR. Pharmacol. Res. Perspect. 3: e00152.
Flume, P.A., Liou, T.G., Borowitz, D.S., Li, H., Yen, K., Ordoñez, C.L., et al. (2012).
Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR
mutation. Chest 142: 718–724.
Fu, J., Ji, H.L., Naren, A.P., and Kirk, K.L. (2001). A cluster of negative charges at the amino
terminal tail of CFTR regulates ATP-dependent channel gating. J. Physiol. 536: 459–470.
Galietta, L.J., Haggie, P.M., and Verkman, A.S. (2001a). Green fluorescent protein-based
halide indicators with improved chloride and iodide affinities. FEBS Lett. 499: 220–224.
Galietta, L.J., Springsteel, M.F., Eda, M., Niedzinski, E.J., By, K., Haddadin, M.J., et al.
(2001b). Novel CFTR chloride channel activators identified by screening of combinatorial
libraries based on flavone and benzoquinolizinium lead compounds. J. Biol. Chem. 276:
19723–19728.
Gregory, R.J., Rich, D.P., Cheng, S.H., Souza, D.W., Paul, S., Manavalan, P., et al. (1991).
Maturation and function of cystic fibrosis transmembrane conductance regulator variants
bearing mutations in putative nucleotide-binding domains 1 and 2. Mol. Cell. Biol. 11: 3886–
3893.
Haws, C.M., Nepomuceno, I.B., Krouse, M.E., Wakelee, H., Law, T., Xia, Y., et al. (1996).
Delta F508-CFTR channelsꢀ : kinetics , activation by forskolin , and potentiation by
xanthines. Am. J. Physiol. Cell Physiol. 270: C1544-1555.
He, L., Kota, P., Aleksandrov, A.A., Cui, L., Jensen, T., Dokholyan, N. V, et al. (2013).
Correctors of ΔF508 CFTR restore global conformational maturation without thermally
stabilizing the mutant protein. FASEB J. 27: 536–545.
Hildebrandt, E., Ding, H., Mulky, A., Dai, Q., Aleksandrov, A.A., Bajrami, B., et al. (2015).
A Stable Human-Cell System Overexpressing Cystic Fibrosis Transmembrane Conductance
This article is protected by copyright. All rights reserved.